Price T Rowe Associates Inc Kura Oncology, Inc. Call Options Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KURA
# of Institutions
184Shares Held
79.6MCall Options Held
148KPut Options Held
63K-
Suvretta Capital Management, LLC New York, NY7.07MShares$126 Million6.08% of portfolio
-
Black Rock Inc. New York, NY6.97MShares$124 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.81MShares$103 Million4.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY5.41MShares$96.2 Million2.34% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.54MShares$80.7 Million3.78% of portfolio
About Kura Oncology, Inc.
- Ticker KURA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,893,000
- Market Cap $1.19B
- Description
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...